A trend to watch in cardiology | FDA clears new-look robotic system | ‘Father of ECMO’ remembered | Pill lowers cholesterol

Sahil Parikh, MD, said it was clear at TCT 2025 that the specialty is getting more and more involved with endovascular procedures for stroke, pulmonary embolism and peripheral artery disease.

GenesisX represents the company’s most accessible robotic system to date. It requires no room shielding or structural anchoring, for example, and the size has been significantly reduced.

Robert H. Bartlett, MD, was a pioneer surgeon who helped develop the world's first ECMO technology. He died at the age of 86 following a long illness. 

The new drug from Merck was linked to several benefits for patients who are already on statins. If an oral PCSK9 inhibitor gains FDA approval, it could be a game-changer for the field of preventive medicine. 

Researchers tracked data from nearly 8,000 patients evaluated with Heartflow's FDA-cleared Plaque Analysis software. Overall, the technology's Plaque Staging feature was found to provide significant value during the diagnosis and management of these patients.

The rise of these medications continues to be one of the biggest stories in healthcare.

Noninvasive coronary CT angiography is growing more and more important as time goes on, helping cardiologists make critical treatment decisions. Carlos Collet, MD, PhD, discussed the technique's potential to be a real game-changer for patient care in a new interview. 

Taking melatonin for a year could increase a person's risk of developing heart failure by 90%. While more research is still needed to confirm these findings, the data suggest patients should think twice about relying on melatonin to sleep. 

When the FDA approved elamipretide for the treatment of Barth syndrome, not everyone agreed with the agency's decision. 

According to the FDA, the drugs are not dissolving correctly. This can impact their ability to lower a patient’s cholesterol as intended.

After President Donald Trump told reporters he underwent an MRI—adding that the results were “perfect”—it remains unclear why, exactly, the scan was ordered in the first place.

PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025. 

The outpatient imaging center operator's latest financial report highlights positive trends “in virtually all aspects of the business.”

Nasser Mohamed, MD, a neurologist who operates a clinical practice in San Francisco, said an artificial intelligence system used by the autonomous taxi company led to him being denied multiple rides. He is seeking injunctive relief.